每经记者｜许立波 每经编辑｜陈俊杰 9月16日，港股上市创新药企业药捷安康（HK02617）股价出现大幅波动。盘中，药捷安康曾大涨 63%，最高每股报679.5港元，市值逼近2700亿港元，在国内创新药企业中市值仅次于恒瑞医药、百济 神州两家龙头。但到下午两点，药捷安康股价遭遇大幅跳水，由大涨转大跌，截至当日收盘，报192.00 港元/股，下跌53.73%，市值缩水至762亿港元。 对于股价异动，药捷安康曾在当日午间披露公告称："概不知悉股价异动原因，业务营运及财务状况无 重大变动。" 公司目前没有商业化产品 药捷安康是一家以临床需求为导向、处于注册临床阶段的生物制药公司，专注于发现及开发肿瘤、炎症 及心脏代谢疾病小分子创新疗法。药捷安康目前还没有商业化产品，今年上半年，公司营业收入为0， 亏损1.23亿元。 药捷安康是一只典型的港股"小盘股"。资料显示，公司于今年6月23日正式登陆港交所。此次IPO（首次 公开募股），药捷安康发行价13.15港元，总股本约3.97亿股，IPO公开发行1528.1万股，除去基石投资 者认购的约979万股，实际流通股仅约549万股。市场流通盘小意味着药捷安康在二级市场上的可交易 ...

为吸引全球顶尖人才并强化创新生态系统，中国推出一系列新举措，为科技领域专业人才提供更便利的 入境条件。北京上个月宣布推出针对外国青年科技人才的K字签证，自10月1日起施行。持K字签证人员 可在华从事教育、科研、文化交流、创业或商业活动。 香港《南华早报》9月15日文章，原题：为何尽管存在一些障碍，欧洲年轻人依然能在中国找到自己的 未来 欧洲人正谨慎地重新燃起对在中国寻求机会的兴趣。对许多渴望在全球范围内寻找机遇的欧洲人 来说，中国在技术、创新等领域仍展现出巨大潜力。斯德哥尔摩大学欧洲知识产权法硕士研究生西蒙· 沃尔德说："这不仅关乎职业发展，还关乎成为这个快速变化体系的一部分。"他认为，在知识产权保护 不断发展的中国工作，"要比留在一切已成定局、体制僵化的欧盟地区有趣得多"。 沃尔德说不同年龄层的人对中国也存在看法差异，"和我交谈过的年轻人都对在中国工作这个想法很感 兴趣。他们看到深圳的崛起、上海的基础设施以及整个中国的发展速度，充满好奇。而一些年长者则往 往警告不要去中国，提到污染、贫穷和发展滞后等，但他们对中国的印象停留在上世纪80年代。当我向 他们展示现代中国的真实面貌时，他们感到震惊"。沃尔德认为中文 ...

证券代码：603566 证券简称：普莱柯 公告编号：2025-038 普莱柯生物工程股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025年9月16日 (二)股东大会召开的地点：河南省洛阳市洛龙区政和路15号公司二楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (五)公司董事、监事和董事会秘书的出席情况 3、董事会秘书出席会议；部分高级管理人员列席会议。 二、议案审议情况 (一)非累积投票议案 1、议案名称：关于公司 2025 年半年度利润分配方案的议案 审议结果：通过 表决情况： ■ ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由公司董事会召集，由董事长张许科先生主持，本次会议以现场投票与网络投票相结合的方式召 开，北京德恒律师事务所律师出席了现场会议并见证。本次会议的召集、召开符合《公司法》《公司章 程》等 ...

Core Insights - Saudi Arabia and the UAE are the top investment destinations for Chinese companies in the Middle East, attracting 84% and 79% of surveyed firms respectively [1] - 90% of Chinese companies plan to expand their business in the Middle East, with 44% having formal plans in place [1] - Over 60% of respondents express satisfaction with their investments, indicating the region's growing importance in Chinese corporate strategies [1] Investment Trends - Saudi Arabia is favored for its rapid economic transformation and large market size, while the UAE is recognized for its role as a diversified investment hub [1] - The shift from representative offices to direct service through physical entities is evident, with 77% of companies now operating this way, reflecting a transition from "testing the waters" to "long-term commitment" [1] - Emerging sectors such as digital technology, renewable energy, artificial intelligence, and biopharmaceuticals are attracting increased interest from investors [1] Regulatory Environment - 72% of companies seek tax incentives outside of free zones, highlighting a demand for cost efficiency [1] - 74% of respondents call for a more transparent and efficient regulatory framework, emphasizing the importance of policy clarity and governance systems for investors [1]

Core Viewpoint - The company, Chengdu Olin Biological Technology Co., Ltd., is focusing on enhancing its market position through medical education and product promotion while advancing its vaccine research and clinical trials for Staphylococcus aureus and influenza vaccines [1][2]. Financial Performance - In the first half of 2025, the company achieved a revenue of 306 million yuan, representing a year-on-year growth of 35.17% [1]. - The net profit attributable to shareholders was 13.2 million yuan, with a net profit of 7.72 million yuan after deducting non-recurring gains and losses, marking a turnaround from losses in the previous year [1]. R&D Pipeline - The company is focusing on two strategic directions: "super bacteria" vaccines and "adult vaccines," continuously enriching its pipeline and enhancing innovation capabilities [2]. - The company is researching four "super bacteria" vaccines, including recombinant Staphylococcus aureus vaccine, oral recombinant Helicobacter pylori vaccine, recombinant Pseudomonas aeruginosa vaccine, and recombinant Acinetobacter baumannii protein vaccine, all classified as global Class 1 new drugs [2]. Clinical Trials - The recombinant Staphylococcus aureus vaccine has completed Phase I and II clinical trials, with Phase III trials currently ongoing and leading globally [2]. - The vaccine aims to prevent Staphylococcus aureus infections post-surgery, with no similar products available globally, indicating a broad application potential in hospital infection prevention [3]. - The company’s Helicobacter pylori vaccine received Phase I clinical trial approval in Australia in 2024, and further optimization of the oral formulation is underway for future domestic clinical trial applications [3]. Technological Advancements - The company is expanding its technological platforms and has made significant progress in the field of viral vaccines, having initiated Phase I clinical trials for trivalent and quadrivalent influenza virus split vaccines in the first half of 2025 [3].

证券时报·数据宝统计显示，舒泰神今日收盘价为38.14元，下跌1.01%，日换手率为4.54%，成交额为 7.89亿元，全天主力资金净流出7179.13万元，近5日该股累计下跌0.70%，近5日资金合计净流出3.33亿 元。 据天眼查APP显示，舒泰神(北京)生物制药股份有限公司成立于2002年08月16日。注册资本47777.2555 万人民币。（数据宝） 舒泰神9月16日大宗交易平台共发生9笔成交，合计成交量465.87万股，成交金额1.51亿元。成交价格均 为32.42元，相对今日收盘价折价15.00%。从参与大宗交易营业部来看，机构专用席位共出现在9笔成交 的买方或卖方营业部中，合计成交金额为1.51亿元，净买入1.51亿元。 进一步统计，近3个月内该股累计发生11笔大宗交易，合计成交金额为1.55亿元。 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折溢 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 价（%） | 业部 | | | 123.87 | 4015.87 | 32.42 | ...

Core Viewpoint - Yifang Biotechnology (益方生物-U) experienced significant trading activity on September 16, with a total of 570,000 shares traded, amounting to 16.91 million yuan, indicating a trend of discounted transactions relative to the closing price [2][3]. Trading Activity - On September 16, three block trades were executed, with a total trading volume of 570,000 shares and a total transaction value of 16.91 million yuan [2]. - All three block trades were conducted at a discount to the closing price, with the average discount ranging from 15.37% to 16.78% [3]. - Institutional participation was noted in one of the trades, with a net purchase amounting to 11.21 million yuan [2]. Recent Performance - Over the past three months, Yifang Biotechnology has recorded a total of 49 block trades, with a cumulative transaction value of 327 million yuan [2]. - The closing price on September 16 was 35.45 yuan, reflecting a decrease of 2.56%, with a daily turnover rate of 2.82% and a total trading volume of 419 million yuan [2]. - In the last five days, the stock has increased by 4.60%, although there has been a net outflow of funds totaling 73.21 million yuan [2]. Financing Data - The latest margin financing balance for Yifang Biotechnology stands at 15.9 million yuan, having decreased by 1.4 million yuan over the past five days, representing a decline of 8.08% [3]. Company Background - Yifang Biotechnology (Shanghai) Co., Ltd. was established on January 11, 2013, with a registered capital of 5.783 billion yuan [3].

每经编辑｜黄胜 9月16日，昊海生科（688366.SH）公告称，公司控股股东、实际控制人之一蒋伟于2025年5月收到中国证监会出具的《立案告知书》。因其涉嫌内幕交易， 中国证监会决定对其立案。近日，公司收到蒋伟通知，获悉其收到中国证监会出具的《行政处罚事先告知书》。该《行政处罚事先告知书》所涉主体为蒋伟 个人，涉及的事项与公司无关。蒋伟不参与公司日常经营管理，该事项不会对公司日常经营、业务及财务造成重大影响。 图片来源：视觉中国-VCG211322973159 | | | | 前 10 名股东持股情况(不含通过转融通出借股份) | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 股东性质 | 持股数量 | 持股比 例(%) | 持有有 限售条 | 包含转融通 借出股份的 | 质押、标记或冻结 情况 | | | | | | | 件股份 | 限售股份数 | 股份状 | | | | | | | 数量 | 喜 | 不 | 数量 | | 将伟 | 境内自然人 | 66,528,000 | 28.53 | 0 | 0 | 元 | 0 ...

Core Insights - The company, Jitai Technology, has launched the world's first AI-driven nano delivery platform, NanoForge, which integrates quantum chemistry and molecular dynamics simulations for drug delivery optimization [1][2] - NanoForge enables a closed-loop process from molecular generation to formulation design, leveraging a large-scale library of over 10 million LNP lipid structures [1][2] - Jitai Technology has developed three major solutions based on NanoForge: AiLNP, AiRNA, and AiTEM, focusing on nucleic acid delivery, mRNA sequence design, and small molecule formulation design respectively [1][2] Company Developments - Jitai Technology has identified LNP targeted delivery for eight organs or tissues, with over 100 authorized and filed patent applications [2] - The company has successfully developed more than 10 pipeline projects, producing 7 preclinical candidates and advancing 4 clinical projects, with the fastest pipeline reaching the pre-NDA stage [2] - The CEO of Jitai Technology emphasized the shift from biotechnology to tech-driven biology, highlighting the efficiency and technological breakthroughs achieved through the integration of large model innovations and iterative experiments [2] Financial and Strategic Moves - In August, Jitai Technology completed a Series D financing round, raising a total of 400 million yuan, led by the Beijing Pharmaceutical Health Industry Investment Fund and the Daxing District Industrial Investment Fund [2] - The funds raised will accelerate the company's strategic initiatives, including platform automation upgrades, advancement of self-developed product pipelines, deepening international collaborations, and attracting high-end talent [2]

证券日报网讯沃森生物（300142）9月16日在互动平台回答投资者提问时表示，关于公司研发投入的相 关情况请具体查阅公司已披露的历次定期报告相关内容，并以定期报告的数据为准。 ...